DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,756 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $72.00, for a total value of $1,926,432.00. Following the sale, the insider owned 355,726 shares in the company, valued at $25,612,272. This represents a 7.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 1.6%

Shares of DXCM stock traded up $1.19 during mid-day trading on Tuesday, reaching $73.57. 5,568,859 shares of the stock traded hands, compared to its average volume of 5,328,045. The stock’s fifty day simple moving average is $68.50 and its two-hundred day simple moving average is $68.23. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a market cap of $28.39 billion, a price-to-earnings ratio of 31.44, a price-to-earnings-growth ratio of 1.17 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The firm’s revenue was up 15.0% compared to the same quarter last year. On average, research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Sanford C. Bernstein set a $77.00 target price on DexCom in a report on Friday, May 1st. TD Cowen restated a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a research report on Wednesday, June 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $88.00 price objective (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 target price on shares of DexCom in a report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $84.88.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently modified their holdings of DXCM. Trust Co. of Vermont lifted its position in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after acquiring an additional 145 shares in the last quarter. CVA Family Office LLC increased its holdings in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of DexCom by 15.4% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after purchasing an additional 153 shares during the last quarter. V Square Quantitative Management LLC raised its stake in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Finally, Essex Financial Services Inc. lifted its holdings in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after purchasing an additional 175 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.